Ignite Creation Date:
2024-05-05 @ 4:49 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00326131
Status:
TERMINATED
Last Update Posted:
2010-03-02
First Post:
2006-05-15
Brief Title:
A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Pharmacokinetics and Metabolism of 14C BMS-275183 in Patients With Advanced Cancer
Status:
TERMINATED
Status Verified Date:
2007-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The first purpose of this study is to determine how the body absorbs metabolizes and eliminates a single dose of BMS-275183 labeled with radioactive carbon Secondly to measure the levels of BMS-275183 in your blood study the safety of the drug and to see what effects it has on your cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None